Stability of spinal bone metastases in breast cancer after radiotherapy

This analysis was based on 115 patients, whose 157 osseous lesions were treated by RT for metastases of the vertebral column due to histologically diagnosed breast carcinoma from January 2000 to January 2012. Patients underwent regular follow-up examinations including computer tomography (CT) imaging.

Patients with osteolytic metastases, localization in the thoracic and lumbar spine, and a minimum duration of follow-up treatment of 6 months were included in this retrospective analysis. Patient data were taken from a cancer registry. Patients who were irradiated in several regions were regarded separately for each region in our analysis. Within each region, the most severe metastasis according to the Taneichi score was included in the analysis [6]. Accordingly, 115 patients with 157 irradiated regions, including 480 vertebral bodies in the thoracic and lumbar spine, were evaluated. For each region one metastasis with the highest probability of collapse according to the Taneichi score was chosen for the examination.

All patients were female. The most frequent histological type was invasive ductal carcinoma (79 %). The Karnofsky Performance Status Scale (KPS) was used to assess performance status [5]. The diagnosis of bone metastasis was made on the basis of the CT or magnetic resonance imaging (MRI) findings or bone scintigraphy investigations. The patient characteristics are summarized in Table 1.

The stability of each affected vertebral body was assessed according to the Taneichi score on the basis of the CT image recorded before RT to plan treatment and also in the follow-up stage 3 and 6 months after radiotherapy [6].

The osteolytic metastases were rated on a scale from A to G. Subtypes A to C were defined as stable, subtypes D to G as unstable (Fig. 1).

Most patients received additional chemotherapy, endocrine therapy, or bisphosphonates before and after RT. After RT, 91 % of the lesions were treated with bisphosphonates (Table 2), and 61 % of the patients were equipped with an orthopedic thoracic corset.

This study was approved by the institutional ethics committee on 22 October 2012 (nr. S-513/2012).

The median follow-up of all patients was 16.7 months (mean 19.9, range 0.4–74.7 months). Thirty patients (19 %) died during follow-up. Seventy patients (61 %) had only bone metastases, 45 patients (39 %) had metastases in other distant organs such as t5he liver (n = 22), lung (n = 19), and brain (n = 11).

Before RT, 46 % (n = 72) of the lesions were classified as stable according to the Taneichi score. Of the stable bone metastases, none were rated unstable in the further course of study (p < 0.001, McNemar test).

Of the 85 patients (54 %) in whom the metastases were classified as unstable prior to RT, 24 patients were classified as stable after 3 months, and 35 patients stable after 6 months. This means that in total, 61 and 68 % of the bone metastases were stable after 3 and 6 months, respectively (Table 3).

The evaluation of the distribution of subtypes A to G showed a major change in the direction of improvement over the course of time. Improvement in the score occurred in 61 % patients (n = 95). Improvement of stability was detected in 22 % (n = 35) of all cases. This corresponds to an improvement of stability in 45 % of all unstable lesions (n = 85). Deterioration of stability was detected in 2 % of cases (n = 3). The Bowker test shows the distribution pattern of the subtypes according to the Taneichi score prior to and 6 months after RT. Asymmetry was apparent (p = 0.0001) and the correlation (weighted kappa = 0.67) was good (Table 4).

Furthermore, there was no significant correlation in the univariate analysis between stability after RT and the potential predictive factors such as bisphosphonates, chemotherapy, and hormone therapy before and after RT. Further factors tested in the univariate analysis were age, KPS, hormone receptor status, histology, and location of the examined metastasis (lumbar spine vs. thoracic spine; Table 3).

Overall survival was 83 % at 5 years for all patients (Fig. 2). The 5-year survival rate for patients with one treated metastasis and more than one metastasis was 88 and 79 %, respectively. Bone survival for all patients was 69 % (Fig. 3), and 74 and 59 % for patients with one and more than one treated metastasis, respectively.

The difference between the subgroups of patients with one and more than one metastasis in both measured periods, overall survival and bone survival, was not significant, with a p value of 0.12 and 0.078, respectively, in the log-rank test.

Besides pain, the reduced stability is the most frequent reason for radiation of bone metastases. The scoring system by Taneichi et al. classifies osteolytic metastases of the thoracic and lumbar spine by risk factors such as tumor size and involvement of costovertebral joints for the thoracic region (Th 1 to 10) and by tumor size and destruction of the pedicles for the lumbar region (Th11, Th12, and all lumbar vertebrae). Posterior elements seem to have a major impact on stabilization, which was found in biometrical models of the thoracic and lumbar spine vertebrae [7‐9].

Before RT, 46 % of the lesions (n = 72) were classified as stable, and after 6 months 70 % (n = 110) were stable. Patients benefit from stabilized metastases in daily life, as soon as they can omit their corset.

In patients who were treated before the validated score was introduced in the facility in 2011, stability of osteolytic bone lesions was estimated on the basis of several factors such as involvement of the rear edge at the vertebral foramen and pain. According to the documentation, 67 % of the irradiated metastases were unstable. Applying the validated score retrospectively, 54 % of the metastases were rated unstable. The difference is result of the changed criteria.

Fractures were detected in 30 lesions. The follow-up examinations revealed seven patients with progressive bone destruction or new fracture.

According to the literature, symptomatic spinal cord compression in patients with bone metastases can be expectedin 10 % of all cases [4]. The patients included in our analyses showed less frequent and less severe neurologic deficits. The reasons might be a preference of surgical treatment for certain patients’ metastatic spinal cord compression and the poor prognosis of patients with inoperable compression, leading to their disqualification for this analysis due to a lack of follow-up examinations. In our analy­sis three patients had existing symptomatic spinal cord compression. A further four patients revealed less severe deficits, such as incomplete paralyses or disorders in the function of the bowl or bladder due to metastases in the further course of the disease and more than 6 months after RT. Complete paraplegia developed in one pa­tient several years after RT.

The rarity of neurological signs might be caused by the preference of surgery in these patients, as it offers immediate decompression of the spinal cord and stabilization [10]. In the analyzed cases, RT was preferably applied to prevent neurologic symptoms and pain caused by collapsing metastases.

All examined factors such as age, KPS, hormone receptor status, histology of the primary tumor, and location of the examined metastasis failed to show significant influence on the probability for restabilization after RT. The concomitant therapy with hormone therapy, chemotherapy, and bisphosphonates therapy also did not show any favorable influence in our analysis. Similar results were already observed in an analysis of bone metastases in lung cancer patients [11].

The predominately used dose schedules for the analyzed cases were 10 fractions of 3 Gy, 14 fractions of2.5 Gy, and 20 fractions of 2 Gy. As suggested by current guidelines, the fractionation schemes were individually selected regarding multiple factors such as prognosis and general state [11]. One can assume that prolonged radiation has a longer lasting effect on bone metastases and a minor probability of in-field recurrences. Considering the available data from the literature, there seem to be few distinctions between the applied fractionations [1, 4]. The analysis consistently showed no significant difference in the fractionation schedules used in our study.

Remarkably, this analysis focused on stabilization of irradiated metastasis within 6 months. This implies that there might be limitations, when examining the influence of systemic or long-term therapies.

Improvements in the therapy of bone metastases were accomplished by concomitant drug therapy such as bisphosphonates [12]. Several trials showed that concomitant bisphosphonates therapy seems to be secure and is assumed to support recalcification. Nevertheless, there is no evidence from controlled prospective trials of the superiority of a combined therapy compared with RT alone [1]. One recent similar analysis, examining predictive factors for survival of de novo bone-metastasized breast cancer patients, suggests that bisphosphonate treatment might be linked to longer overall survival. According to this report, patients receiving hormone therapy or chemotherapy had no significant survival benefit [13]. Further reports did not find a benefit when comparing the hormone receptor status with the probability for skeletal complications [14]. In our analysis we could not detect a benefit for hormone or chemotherapy after RT concerning the endpoint stabilization.

The median overall survival for metastatic breast cancer is long (several years) when compared with other tumors such as lung cancer [15‐17]. In our analysis, we measured a survival of 82 % after 5 years, which is longer than the overall survival measured in similar studies [10]. The extended survival might be a manifestation of the selection criteria, by only including patients with at least 6 months of follow-up. This is also illustrated by the high initial KPS with median value of 80.

Prolonged survival is associated with absent extraskeletal metastases, which was the case in most patients. Sung et al. reported a median survival after the diagnosis of bone-only metastases of 75 months [95 % confidence interval (CI), 38.6–71.9] with increased survival of de novo bone metastases [13]. The number of patients with de novo and bone-only metastases in our analyses was high at 45 %. The comparatively high estimated survival rates emphasize the need for a palliative therapy that is not restricted to pain relief but preserves the patient’s physical autonomy.

The use of a systematic radiological scoring system to classify osteolytic metastases of the vertebral column was shown to be practicable for patients with metastasized breast cancer in the follow-up period after RT, and should be applied in daily routine. The majority of patients showed an improved or unchanged stability of their involved vertebral bodies after 6 months.